RENAL TRANSPLANTATION
The success of renal transplantation, which
is largely due to advances in immunosuppressive therapy, has greatly improved
the quality of life for patients with end-stage renal disease. With modern
immu-nosuppressive regimens, cadaveric transplants have achieved almost the
same 80–90% 3-year graft sur-vival rate as living-related donor grafts. In
addition, restrictions on candidates for renal transplantation have gradually
decreased. Infection and cancer are the only remaining absolute
contraindications.
Current organ preservation techniques allow
ample time (24–48 h) for preoperative dialysis of cadaveric recipients.
Living-related transplants are performed
electively with simultaneous donor and recipientoperations. The recipient’s
serum potassium concentration should be below 5.5 mEq/L, andexisting
coagulopathies should be corrected.
Renal transplantation is carried out by
placing the donor kidney retroperitoneally in the iliac fossa and anastomosing
the renal vessels to the iliac vessels and the ureter to the bladder. Heparin
is adminis-tered prior to temporary clamping of the iliac vessels. Intravenous
mannitol administered to the recipient helps establish an osmotic diuresis
following reper-fusion. Immunosuppression is initiated on the day of surgery
with combination medications which may include corticosteroids, cyclosporine or
tacro-limus, azathioprine or mycophenolate mofetil, anti-thymocyte globulin,
monoclonal antibodies directed against specific subsets of T lymphocytes
(OKT3), and interleukin-2 receptor antibodies (daclizumab or basiliximab). The
anesthetist should discuss in advance with the surgery team the timing and
dos-age of any immunosuppressive agents which will need to be given perioperatively.
Recipient nephrec-tomy (with a failed transplant) is performed for intractable
hypertension or chronic infection.
Most renal transplants are performed with general anesthesia, although
spinal and epidural anesthesiaare also utilized. All general anesthetic agents
have been employed without any apparent detrimen-tal effect on graft function.
Cisatracurium and rocuronium may be the muscle relaxants of choice, as they are
not dependent upon renal excretion for elimination. Vecuronium may be used with
only modest prolongation of its effects.
Central venous cannulation may be useful for ensuring adequate hydration
while avoiding fluid overload, particularly in patients with impaired cardiac
status. Central lines are also useful portals for the various infusions that
these patients require in the first few days after transplant. Normal saline is
commonly used. A urinary catheter is placed preoperatively, and a brisk urine
flow following the arterial anastomosis generally indicates good graft
function. If the graft ischemic time was prolonged, an oliguric phase may
precede the diuretic phase, in which case fluid therapy must be appropriately
adjusted. Administration of furosemide or addi-tional mannitol may be indicated
in such cases. Hyperkalemia has been reported after release of the vascular
clamp following completion of the arterial anastomosis, particularly in
pediatric and other small patients, and release of potassium con-tained in the
preservative solution has been impli-cated as the cause of this phenomenon.
Donor kidney washout of the preservative solution with ice-cold lactated
Ringer’s solution just prior to the vascular anastomosis may help avoid this
problem. Serum electrolyte concentrations should be moni-tored closely after
completion of the anastomosis. Hyperkalemia may be suspected from peaking of
the T wave on the ECG.
Related Topics
Privacy Policy, Terms and Conditions, DMCA Policy and Compliant
Copyright © 2018-2024 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.